Gilead to acquire Arcellx to gain full control of anito-cel

Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial

AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL

Vanda Pharmaceuticals' BYSANTI (milsaperidone) tablets receive US FDA approval

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons

Hansa's imlifidase Biologics License Application accepted by FDA

Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria

Cambridge Cognition expands into India through Ivory commercialisation agreement

HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer

STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)

MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy

Pegasus Laboratories' KBroVet receives full FDA approval for control of seizures associated with IE in dogs